<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03359174</url>
  </required_header>
  <id_info>
    <org_study_id>2000021447</org_study_id>
    <nct_id>NCT03359174</nct_id>
  </id_info>
  <brief_title>An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis</brief_title>
  <official_title>An Efficacy Trial of Low Dose All-trans Retinoic Acid (ATRA) in Patients With Primary Sclerosing Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether a low dose of ATRA will improve&#xD;
      laboratory tests of liver and bile duct inflammation in patients with PSC. The investigators&#xD;
      will also look for changes to other blood tests which are related to inflammation, scarring,&#xD;
      and the immune system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">May 29, 2018</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Serum Alkaline Phosphatase (ALP)</measure>
    <time_frame>Baseline to week 24.</time_frame>
    <description>Blood will be drawn at each time point to compare pre- and post-treatment values for each individual.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Patients Who Have Normalization of Serum ALP or Reduction to Less Than 1.5 x Upper Limit of Normal (ULN)</measure>
    <time_frame>Baseline to week 24.</time_frame>
    <description>Blood is drawn at each time point to assess the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent of Patients Who Have Reduction of Serum C4 by 50%</measure>
    <time_frame>Baseline to week 24.</time_frame>
    <description>Blood is drawn at each time point to assess the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent of Patients Who Have Reduction of Serum Bile Acids by 50%</measure>
    <time_frame>Baseline to week 24.</time_frame>
    <description>Blood is drawn at each time point to assess the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent of Patients Who Have Reduction of Serum Alanine Aminotransferase (ALT) by 50%</measure>
    <time_frame>Baseline to week 24.</time_frame>
    <description>Blood is drawn at each time point to assess the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent of Patients Who Have Reduction of Serum Enhanced Liver Fibrosis Score (ELF) by 10%</measure>
    <time_frame>Baseline to week 24.</time_frame>
    <description>Blood is drawn at each time point to assess the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent of Patients Who Have Improvement in Fibrosis Per Transient Elastography by at Least 1 Stage</measure>
    <time_frame>Baseline to week 24.</time_frame>
    <description>Transient Elastography will be performed at baseline and week 24 to assess the outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Cholangitis, Sclerosing</condition>
  <arm_group>
    <arm_group_label>All-trans retinoic acid (ATRA) therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed low dose of ATRA 10 mg twice daily for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>All-trans retinoic acid</intervention_name>
    <description>Fixed low dose of ATRA 10 mg twice daily for 24 weeks.</description>
    <arm_group_label>All-trans retinoic acid (ATRA) therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females ages 18-80&#xD;
&#xD;
          -  Diagnosis of large-duct PSC based on ERCP or MRCP, or liver biopsy findings without&#xD;
             alternative explanation for findings, for at least 6 months.&#xD;
&#xD;
          -  Serum ALP levels persistently more than 1.5 x upper limit of normal over the past 6&#xD;
             months.&#xD;
&#xD;
          -  Ursodeoxycholic acid therapy must be discontinued for at least 3 months.&#xD;
&#xD;
          -  At least 2 forms of barrier protection for males and females of child-bearing age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Small duct PSC, overlap with autoimmune hepatitis, IgG4 disease or secondary&#xD;
             sclerosing cholangitis.&#xD;
&#xD;
          -  Any malignancy, presently or within the past 5 years, except adequately treated&#xD;
             non-melanoma skin cancer, carcinoma in situ of the cervix or in situ prostate cancer.&#xD;
&#xD;
          -  Viral hepatitis including hepatitis A, B, C, D, E.&#xD;
&#xD;
          -  Decompensated cirrhosis, or planned liver transplantation.&#xD;
&#xD;
          -  Recent diagnostic or therapeutic biliary manipulation (endoscopic, radiologic) within&#xD;
             the past 3 months.&#xD;
&#xD;
          -  Ascending Cholangitis requiring antibiotics within the past 3 months.&#xD;
&#xD;
          -  Uncontrolled IBD, or IBD requiring the use of steroids.&#xD;
&#xD;
          -  Acute or Chronic Kidney Disease with serum creatinine &gt; 2 mg/dL.&#xD;
&#xD;
          -  Allergy to ATRA or vitamin A compounds.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Boyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <results_first_submitted>June 7, 2021</results_first_submitted>
  <results_first_submitted_qc>August 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2021</results_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT03359174/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from physicians case load at Yale University, Digestive Disease's Liver clinic between May 2018 and December 2018. Both participants were enrolled in May of 2018.</recruitment_details>
      <pre_assignment_details>Of the two patients who screened, both met inclusion and exclusion criterial and were enrolled</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All-trans Retinoic Acid (ATRA) Therapy</title>
          <description>Fixed low dose of ATRA 10 mg twice daily for 24 weeks.&#xD;
All-trans retinoic acid: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All-trans Retinoic Acid (ATRA) Therapy</title>
          <description>Fixed low dose of ATRA 10 mg twice daily for 24 weeks.&#xD;
All-trans retinoic acid: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Serum Alkaline Phosphatase (ALP)</title>
        <description>Blood will be drawn at each time point to compare pre- and post-treatment values for each individual.</description>
        <time_frame>Baseline to week 24.</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>All-trans Retinoic Acid (ATRA) Therapy</title>
            <description>Fixed low dose of ATRA 10 mg twice daily for 24 weeks.&#xD;
All-trans retinoic acid: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Serum Alkaline Phosphatase (ALP)</title>
          <description>Blood will be drawn at each time point to compare pre- and post-treatment values for each individual.</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patients Who Have Normalization of Serum ALP or Reduction to Less Than 1.5 x Upper Limit of Normal (ULN)</title>
        <description>Blood is drawn at each time point to assess the outcome.</description>
        <time_frame>Baseline to week 24.</time_frame>
        <population>Only 1 patient completed the study, and no trial end point was achieved so there was no data to record. .</population>
        <group_list>
          <group group_id="O1">
            <title>All-trans Retinoic Acid (ATRA) Therapy</title>
            <description>Fixed low dose of ATRA 10 mg twice daily for 24 weeks.&#xD;
All-trans retinoic acid: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patients Who Have Normalization of Serum ALP or Reduction to Less Than 1.5 x Upper Limit of Normal (ULN)</title>
          <description>Blood is drawn at each time point to assess the outcome.</description>
          <population>Only 1 patient completed the study, and no trial end point was achieved so there was no data to record. .</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent of Patients Who Have Reduction of Serum C4 by 50%</title>
        <description>Blood is drawn at each time point to assess the outcome.</description>
        <time_frame>Baseline to week 24.</time_frame>
        <population>Only 1 patient completed the study, data not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>All-trans Retinoic Acid (ATRA) Therapy</title>
            <description>Fixed low dose of ATRA 10 mg twice daily for 24 weeks.&#xD;
All-trans retinoic acid: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent of Patients Who Have Reduction of Serum C4 by 50%</title>
          <description>Blood is drawn at each time point to assess the outcome.</description>
          <population>Only 1 patient completed the study, data not reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent of Patients Who Have Reduction of Serum Bile Acids by 50%</title>
        <description>Blood is drawn at each time point to assess the outcome.</description>
        <time_frame>Baseline to week 24.</time_frame>
        <population>Only 1 patient completed the study, data not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>All-trans Retinoic Acid (ATRA) Therapy</title>
            <description>Fixed low dose of ATRA 10 mg twice daily for 24 weeks.&#xD;
All-trans retinoic acid: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent of Patients Who Have Reduction of Serum Bile Acids by 50%</title>
          <description>Blood is drawn at each time point to assess the outcome.</description>
          <population>Only 1 patient completed the study, data not reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent of Patients Who Have Reduction of Serum Alanine Aminotransferase (ALT) by 50%</title>
        <description>Blood is drawn at each time point to assess the outcome.</description>
        <time_frame>Baseline to week 24.</time_frame>
        <population>Only 1 patient completed the study, data not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>All-trans Retinoic Acid (ATRA) Therapy</title>
            <description>Fixed low dose of ATRA 10 mg twice daily for 24 weeks.&#xD;
All-trans retinoic acid: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent of Patients Who Have Reduction of Serum Alanine Aminotransferase (ALT) by 50%</title>
          <description>Blood is drawn at each time point to assess the outcome.</description>
          <population>Only 1 patient completed the study, data not reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent of Patients Who Have Reduction of Serum Enhanced Liver Fibrosis Score (ELF) by 10%</title>
        <description>Blood is drawn at each time point to assess the outcome.</description>
        <time_frame>Baseline to week 24.</time_frame>
        <population>Only 1 patient completed the study, data not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>All-trans Retinoic Acid (ATRA) Therapy</title>
            <description>Fixed low dose of ATRA 10 mg twice daily for 24 weeks.&#xD;
All-trans retinoic acid: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent of Patients Who Have Reduction of Serum Enhanced Liver Fibrosis Score (ELF) by 10%</title>
          <description>Blood is drawn at each time point to assess the outcome.</description>
          <population>Only 1 patient completed the study, data not reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent of Patients Who Have Improvement in Fibrosis Per Transient Elastography by at Least 1 Stage</title>
        <description>Transient Elastography will be performed at baseline and week 24 to assess the outcome.</description>
        <time_frame>Baseline to week 24.</time_frame>
        <population>Only 1 patient completed the study, data not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>All-trans Retinoic Acid (ATRA) Therapy</title>
            <description>Fixed low dose of ATRA 10 mg twice daily for 24 weeks.&#xD;
All-trans retinoic acid: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent of Patients Who Have Improvement in Fibrosis Per Transient Elastography by at Least 1 Stage</title>
          <description>Transient Elastography will be performed at baseline and week 24 to assess the outcome.</description>
          <population>Only 1 patient completed the study, data not reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 28 weeks post treatment initiation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All-trans Retinoic Acid (ATRA) Therapy</title>
          <description>Fixed low dose of ATRA 10 mg twice daily for 24 weeks.&#xD;
All-trans retinoic acid: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>alkaline phosphatase increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Coordinator</name_or_title>
      <organization>Yale Univeristy</organization>
      <phone>203 737 6839</phone>
      <email>laura.cusack@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

